Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes  

作　　者：Rayhane Nchioua Federica Diofano Sabrina Noettger Pascal von Maltitz Steffen Stenger Fabian Zech Jan Münch Konstantin M.J.Sparrer Steffen Just Frank Kirchhoff 

机构地区：[1]Institute of Molecular Virology,Ulm University Medical Center,Ulm,Germany [2]Molecular Cardiology,Department of Internal Medicine II,Ulm University,Ulm,Germany [3]Institute of Medical Microbiology and Hygiene,Ulm University Medical Center,Ulm,Germany

出　　处：《Signal Transduction and Targeted Therapy》2023年第1期10-12,共3页信号转导与靶向治疗（英文）

基　　金：supported by the DFG(CRCs 1279 and 1506);the EU commission(Fight-nCoV);the MWK and the BMBF(Restrict-SARS-CoV-2,IMMUNOMOD).

摘　　要：Dear Editor,Since its first description in South Africa in November 2021,the SARS-CoV-2 Omicron variant rapidly outcompeted the previously dominating Delta variant.Omicron is the fifth variant of concern(VOC).It contains an unusually high number of mutations compared to previous VOCs,especially in the viral Spike protein,and shows high transmissibility and efficient escape of neutralizing antibodies.

关 键 词：STRONG neutral OMI 

分 类 号：R373[医药卫生—病原生物学]